(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in one year.

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

Learn how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual ...

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...